Bolivia Approves $1.9 Billion IMF Financing Deal 
LVMH-Hermès Dispute Deepens Over Secret 2002 Share Deal 
Wall Street Surges as Meta Leads AI Rally, Oil Prices Fall 
South Korea to Brief Lawmakers on $350 Billion US Investment Package 
Apple Pay Set for India Launch With Axis Bank 
Paramount-Warner Bros $110 Billion Deal Draws Antitrust Backlash 
France Debt-to-GDP Ratio Seen Hitting Record 119.3% in 2026 
Allegro Raises 2026 Outlook as International GMV Surges 
Yen Weakens as Dollar Gains on Widening US-Japan Rate Gap 
Oil Prices Tumble on U.S.-Iran Diplomacy Hopes, Supply Relief 
S&P 500 Historically Rallies After Midterm Elections, UBS Says 
SpaceX Nasdaq 100 Weight to More Than Double in Rebalance 
Trump Bans CNN, MS NOW and Politico From White House 
UK Home Asking Prices Rise for First Time Since May 
Vietnam Stocks Join FTSE Emerging Market Indexes, Unlocking Billions in Foreign Investment 
Westinghouse Targets $50 Billion Valuation in U.S. IPO 
Add as a preferred source on Google
Samsung Electronics’s executive chairman, Lee Jae Yong, has been holding meetings with leaders of the leading biopharmaceutical and biotechnology companies to forge joint ventures or enter into partnership deals.
The Samsung Electronics chief reportedly met up with global executives of some leading brands in the biotech and biopharma industry, including Johnson & Johnson’s chief executive officer, Joaquin Duato; Biogen’s chief, Christopher Viehbacher; Bristol Myers Squibb’s CEO, Giovanni Caforio; Kevin Ali, Organon’s CEO; and Noubar Afeyan of Flagship Pioneering.
Lee held meetings with them during his recent trip to the United States. Korea Joongang Daily reported that the Samsung leader has a goal of securing partnership agreements with them as he is seeing the biopharma and biotech fields as the company’s new growth drivers.
The Samsung chairman also commented during his trip, "The starting point is not important, but bold and persistent challenges set victory apart from defeat. Let us continue the success story of chips with bio."
In any case, Lee Jae Yong is trying to get contracts for the company’s CMDO arm, Samsung Biologics, which is currently the largest contract manufacturing and development organization in the world based on production capacity.
While it is a latecomer in this market, Samsung Biologics is doing fairly well since it was first established in 2011. Samsung Electronics owns 31.22% of shares in its affiliate CMDO firm.
"The bio-industry is a field with high barriers to entry, requiring not only production technology and R&D capabilities but also trust and reputation building for long-term collaboration,” The Korea Times quoted Samsung as saying in a statement regarding the chairman's move to seek collaborations with US bio companies. “Lee's wide global network is expected to serve as a lever for Samsung's bio business to expand collaboration with big pharmaceutical companies and create future growth opportunities."
